Glypican-2 Antibodies

Glypican-2 (Gpc2)

Cell surface proteoglycan that bears heparan sulfate. May fulfill a function about the motile behaviors of developing neurons (By similarity).

. .

Gene Information

Mouse
Gene Name:	Gpc2
Uniprot:	Q8BKV1
Entrez:	71951

Family

Belongs to:
glypican family

Alternative Names

Cerebroglycan; Glypican 2; GPC2

Molecular Weight

Mass (kDA):
63.344 kDA

Genomic Context

Mouse
Location:	5|5 G2
Sequence:	5;

Diseases

• Tissue Adhesions
• Nervousness
• Neoplasms
• Neuroblastoma
• Extravasation
• Pediatric Neoplasm
• Cardiomyopathy, Familial Idiopathic
• Sarcoma
• Rheumatism
• Hypercholesterolemia
• Mycoplasma Pneumonia

• Malignant Childhood Neoplasm
• Edema
• Malignant Neoplasms
• Inflammation
• Anoxia

Pathways

• Cell Adhesion
• Cell Migration
• Mitosis
• Localization
• Translation
• Sulfation
• Response To Anoxia
• Pollination
• Cell-matrix Adhesion
• Endocytosis

• Cytokinesis
• Leukocyte Migration
• Cell Cycle
• Endosperm Development
• Kidney Development

PTMs

• Glycoprotein
• GPI-anchor

• Heparan sulfate
• Lipoprotein

• Proteoglycan

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/Gpc2

Boster Bio - Best Uses Of The GPC2 Marker

There are many options available when it comes to optimizing your experiment. Boster Bio optimization guides and tips can answer questions and provide guidance on the best way to optimize your experiments. Glypican 2, which is a differentially expressed surface molecule on cells, is thought to be an immunotherapeutic target and a potential oncogene. This article will provide further information on this putative compound.

Glypican 2 can be differentially expressed on cell surfaces

A member of the glypican (GPC) family of genes, Glypican 2 produces a glycosylphosphatidylinositol-anchored proteoglycan with up-to-date evidence of role in cancer. Although glypican 2, a biomarker that can be used to diagnose multiple types of cancers, is not yet well-researched.

Glypican proteins are heparan sulfate proteoglycans that are linked to the cell membrane through a glycosyl-phosphatidylinositol anchor. Glypican proteins are found in six species of mammals. All of these species could be therapeutic targets. Glypicans are widely expressed in cells, including the brain, liver and kidney.

The cellular and molecular basis of glypican activity is unclear, but it has been reported that glypicans interact with various signaling receptors. Some have a role to regulate polyamine uptake. Others are involved in synapse function and morphogenesis. Therefore, a comprehensive understanding of glypican activity is essential to further understand its biological role in cell survival and development.

It is a putative immunotherapeutic target

Vimentin, the intermediate filament protein, is a known target for Boster Bio. Although it is well-known for its intracellular roles, which include promoting angiogenesis in tumors and increasing malignancy, recent studies have suggested that extracellular vimentin may play additional roles. Vimentin helps ECs escape the immune system by externalizing. Anti-tumor growth and vascularization are therefore inhibited by immune checkpoints against extracellular vitaminin.

CTAs are a potential therapeutic target for cancers. These vaccines are targeted at distinct CTAs. Their effectiveness in stimulating clinical responses depends on optimizing strategies for directing the immune system against cancer cells. New therapeutic tools have been developed to improve the immune response.

It is a possibily oncogene

Although the role of GPC1 in cancer development is not fully understood, it has been shown that it plays a significant role. Its expression was also correlated with tumor grade and was associated with an improved prognosis. GPC1 & GPC2 need to be investigated more thoroughly before they can be considered potential oncogenes.

GPC2 expression has been detected in many types of tumors. It is found in many neuroblastoma cell lines and is essential for tumorigenesis. GPC2 immunotherapy strategies are currently being explored. They include antibody-drug conjugates. In the meantime, an immunotherapy target validation platform was created. This immunotherapy research forms part of the St. Baldricks Stand Up Cancer Immunogenomics team.

Interestingly, GPC1 and GPC4 expression were associated with the presence of post-surgical lymph nodes in T1-T4 cancer patients. In addition, the presence of SDC2 and GPC6 was associated with enhanced expression in lymph nodes. Recent research showed that SDC1 and GPC4 expression was independently associated with lymphnodal infiltration after surgery in T1-T2 patients.

Immunohistochemical stainings for glypican 5 showed that tumour cells expressing GPC1 had increased levels of keratinization. GPC3 and GPC4 did not exist in healthy tissues. GPC6 expression was widespread on normal epithelial cells and in the intralesional stromal compartment. GPC6 expression was not significant but could be useful in larger cohorts.

GPC3's role is still unknown in the development certain types of cancer in mice. It has been confirmed that it co-expresses with IGF-II. However, it remains to be determined if it plays any role in carcinogenesis. Although GPC3 is not a known oncogene, it is an important factor in certain types of embryonic development. We will continue to research this area to better understand its role as an embryonic tumor-forming factor.

In a recent study, researchers identified 11 cell surface-associated PGs associated with neoplastic cells. GPC1 and GPC6 were not often found in the intralesional stroma of HNSCC's oral cavity. However, they were more common in tumours. GPC3 (and GPC4) were immunolocalized with epithelial cells and stromal fibrblasts, respectively.

Moreover, NG2/CSPG4 was found to be significantly associated with survival in the HPV-negative/stage-IVa subgroup of HNSCC. It was also found to be associated with the expression other cancer-related gene, such as p53 or ER-alpha, HER2, EGFR and HER2. Moreover NG2/CSPG4 mRNA expression was linked with ovarian ductal adenocarcinoma.